Scarica l'app Stockscreener
55.96
1.04%
-0.59
Dopo l'orario di chiusura:
55.95
-0.010
-0.02%
Precedente Chiudi:
$56.55
Aprire:
$56.925
Volume 24 ore:
2.58M
Relative Volume:
0.96
Capitalizzazione di mercato:
$9.25B
Reddito:
$1.06B
Utile/perdita netta:
$-326.58M
Rapporto P/E:
-26.62
EPS:
-2.1022
Flusso di cassa netto:
$-977.73M
1 W Prestazione:
+5.68%
1M Prestazione:
-31.07%
6M Prestazione:
-31.87%
1 anno Prestazione:
+32.47%
Intervallo 1D:
$55.79
$57.09
Intervallo di 1 settimana:
$50.01
$57.48
Portata 52W:
$40.03
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
55.96 | 9.35B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-04-10 | Ripresa | Raymond James | Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-10-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2025-09-03 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceutica - The National Law Review
Ionis Pharmaceuticals (IONS) Stock Analysis: Uncovering a Potential 62% Upside in the Biotech Sector - DirectorsTalk Interviews
Ionis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:IONS - TradingView
Ionis Pharmaceuticals, Inc. Revenue Breakdown – DUS:ISI - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Connect - ACCESS Newswire
Ionis Pharmaceuticals Inc (IONS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ionis Pharmaceuticals Inc (IONS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Ionis Pharmaceuticals Inc (IONS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ionis Pharmaceuticals Inc (IONS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ionis Pharmaceuticals Inc (IONS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ionis Pharmaceuticals Inc. (IONS) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
IONS|Ionis Pharmaceuticals Inc|Price:56.550|Chg%:+0.680 - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceuticals, Inc. (IONS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
How Eplontersen’s Phase 3 Setback And Scrutiny At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story - Yahoo Finance
Ionis stock trades steady as genetic medicine pipeline advances and revenue grows - Ad-hoc-news.de
Ionis Pharmaceuticals (IONS) Misses A Key Trial Endpoint, Is The Valuation Now Too Harsh? - Yahoo Finance
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High - Investor's Business Daily
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23%HBSS - Morningstar
Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $110 - Moomoo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc.IONS - PR Newswire
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or uniQure N.V. Stock? - AAII
Canaccord reiterates Ionis stock rating on Tryngolza advantage By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Inc (IONS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Arrowhead rises on phase III hypertriglyceridemia readout - BioWorld News
Plozasiran Phase III Results Expand Cardiometabolic Use - AllSci
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug - BioPharma Dive
Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data - Fierce Pharma
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug - BioSpace
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials (NASDAQ:ARWR) - Seeking Alpha
Earnings Preview: Ionis Pharmaceuticals (IONS) Q2 Earnings Expected to Decline - Yahoo Finance
Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug - Seeking Alpha
Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Ionis Pharmaceuticals, Inc. (IONS) Shows Oversold Potential with Low RSI - GuruFocus
How does Biogen’s novel Alzheimer’s drug compare to approved drugs - MSN
2026-07-21 | Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:IONS | Press Release - Stockhouse
Ionis Pharmaceuticals Stock Slides 39% With A 9-Day Losing Spree - Trefis
Guggenheim cuts Ionis stock price target on Tryngolza sales outlook By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Stock Slides 39% Over 9 Straight Down Days - Trefis
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ionis Pharmaceuticals, Inc. (IONS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmac - The National Law Review
Ionis Pharmaceuticals Stock Slides 37% Over 8 Straight Down Days - Trefis
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: A Biotech Leader with a 70.90% Potential Upside - DirectorsTalk Interviews
Ionis Pharmaceuticals (IONS) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr
2026-07-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ionis Pharmaceuticals, Inc. (IONS) and Encourages Stockholders to Learn More About the Investigation | NDAQ:IONS | Press Release - Stockhouse
(IONS) Risk Channels and Responsive Allocation - Stock Traders Daily
Ionis Pharmaceuticals (IONS) Proxy filing Summary - Quartr
Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceuticals, Inc. (IONS) Investors to Inquire about Securities Investigation - ACCESS Newswire
Cathie Wood Just Bet Big on This Biotech Stock - The Motley Fool
Form 4 Ionis Pharmaceuticals Inc For: 17 July By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):